Trial · NCT06551844
Adaptive Dengue Antiviral Platform Trial
NCT06551844, Phase 2, Recruiting, Oxford University Clinical Research Unit, Vietnam
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adaptive Dengue Antiviral Platform Trial. Trials, record NCT06551844. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06551844
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adaptive Dengue Antiviral Platform Trial
- NCT number
- NCT06551844
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 500 participants, estimated
- Lead sponsor
- Oxford University Clinical Research Unit, Vietnam
- Conditions
- Dengue, Antiviral Drugs
- Interventions
- Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg
- First posted
- 2024-08-13
- Last updated
- 2026-09-28
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Viral clearance rate | From randomization until day 5 of study | Rate of viral clearance estimated under a hierarchical log-linear model fit to the serial viral load measurements over 5 days after enrolment. The viremia kinetics will be measured using the qRT-PCR assay, which will be performed on samples taken twice a day from day 1 to day 3 of study and then once a day on days 4 and 5 of study (total 9 samples per patient). |
| Primary | Number of AEs (grade 3, 4 and 5) | Until day 30 post-enrolment | All patients will be followed up daily until discharge and then at around days 30 after randomization to collect information on clinical progress of dengue illness and any adverse events occurring during the study course. All AEs and SAEs will be recorded. |
| Secondary | Area under the viremia curve | From randomisation until day 5 of study | Area under the curve (AUC) of the serial viremia measurements during the first 5 days of study |
| Secondary | Viral log reduction | up to 48 hours of study | Reduction of viremia at the 24 and 48 hours compared to baseline |
| Secondary | NS1 clearance time | up to day 5 | Time to NS1 clearance as estimated under a non-linear model |
| Secondary | Number of patients progress to severe dengue (WHO 2009 criteria) | From enrolment until discharge, assessed up to 30 days | All patients will be followed up daily until discharge to collect information about the clinical progress of dengue |
| Secondary | Number of patients requiring for ICU admission | From enrolment until discharge, assessed up to 30 days | All patients will be followed up daily until discharge to collect information about the clinical progress of dengue |
| Secondary | Fever clearance time | From enrolment until discharge, assessed up to 30 days | Time elapsed from enrolment to the afebrile time-point (defined as body temperature \<37.5 °C for at least 48 hours) |
| Secondary | Platelet nadir | Until day 30 post-enrolment | The lowest platelet count recorded during admission |
| Secondary | Maximum AST/ALT | Until day 30 post-enrolment | The highest values of AST/ALT measured |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06551844
GET https://conductscience.org/api/trials/v1/NCT06551844/registered